AstraZeneca Settles Patent Suit on Copycat Faslodex Cancer Drug

AstraZeneca settled a lawsuit in which it had accused three companies of violating patents with a proposed generic version of Faslodex, an injectable treatment for breast cancer.

• Sino Biopharm’s Chia Tai Tianqing, Athenex, and The WhiteOak Group are blocked from selling their copy of Faslodex “except as specifically authorized” in the settlement agreement, according to consent judgment approved Friday in federal court in Camden, New Jersey
• Faslodex had U.S. sales of $537 million in 2018, 2.6% of AstraZeneca’s revenue, according to data compiled by Bloomberg
• Amneal and Novartis’s Sandoz sell generic versions of FaslodexNOTE: AstraZeneca, Sandoz End Faslodex Patent Dispute ...